Morgan Stanley Greenwich Life Sciences, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 11,766 shares of GLSI stock, worth $108,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,766

Previous 9,547 23.24%

Holding current value

$108,600

Previous $91,000 16.48%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$8.76 - $10.44 $19,438 - $23,166	2,219 Added 23.24%	11,766 $106,000
Q1 2025 May 15, 2025	SELL	$9.54 - $13.43 $40,325 - $56,768	-4,227 Reduced 30.69%	9,547 $91,000
Q4 2024 Feb 14, 2025	SELL	$10.91 - $14.95 $35,533 - $48,692	-3,257 Reduced 19.12%	13,774 $154,000
Q3 2024 May 14, 2025	BUY	$12.99 - $17.58 $129,614 - $175,413	9,978 Added 141.47%	17,031 $244,000
Q3 2024 Nov 14, 2024	BUY	$12.99 - $17.58 $129,614 - $175,413	9,978 Added 141.47%	17,031 $244,000
Q2 2024 May 14, 2025	SELL	$12.07 - $19.04 $81,122 - $127,967	-6,721 Reduced 48.79%	7,053 $121,000
Q2 2024 Oct 17, 2024	BUY	$12.07 - $19.04 $9,933 - $15,669	823 Added 13.21%	7,053 $121,000
Q2 2024 Aug 14, 2024	BUY	$12.07 - $19.04 $9,933 - $15,669	823 Added 13.21%	7,053 $121,000
Q1 2024 Oct 17, 2024	SELL	$8.31 - $20.32 $6,839 - $16,723	-823 Reduced 11.67%	6,230 $124,000
Q1 2024 Aug 16, 2024	BUY	$8.31 - $20.32 $49,444 - $120,904	5,950 Added 2125.0%	6,230 $124,000
Q1 2024 May 15, 2024	BUY	$8.31 - $20.32 $49,444 - $120,904	5,950 Added 2125.0%	6,230 $124,000
Q4 2023 Aug 16, 2024	SELL	$7.77 - $12.3 $52,626 - $83,307	-6,773 Reduced 96.03%	280 $2,000
Q3 2023 Nov 15, 2023	SELL	$8.41 - $10.66 $4,011 - $5,084	-477 Reduced 63.01%	280 $2,000
Q2 2023 Aug 14, 2023	SELL	$9.58 - $13.2 $60,986 - $84,031	-6,366 Reduced 89.37%	757 $7,000
Q1 2023 May 15, 2023	SELL	$12.12 - $20.8 $19,392 - $33,280	-1,600 Reduced 18.34%	7,123 $98,000
Q4 2022 Feb 14, 2023	SELL	$9.04 - $16.88 $239,668 - $447,522	-26,512 Reduced 75.24%	8,723 $132,000
Q3 2022 Nov 14, 2022	SELL	$7.81 - $12.02 $296,428 - $456,219	-37,955 Reduced 51.86%	35,235 $321,000
Q2 2022 Oct 27, 2022	BUY	$7.14 - $20.36 $367,588 - $1.05 Million	51,483 Added 237.17%	73,190 $619,000
Q2 2022 Aug 15, 2022	BUY	$7.14 - $20.36 $367,588 - $1.05 Million	51,483 Added 237.17%	73,190 $619,000
Q1 2022 Oct 27, 2022	SELL	$16.3 - $24.65 $839,172 - $1.27 Million	-51,483 Reduced 70.34%	21,707 $426,000
Q1 2022 May 13, 2022	SELL	$16.3 - $24.65 $235,551 - $356,217	-14,451 Reduced 39.97%	21,707 $426,000
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $771,631 - $1.4 Million	35,461 Added 5087.66%	36,158 $879,000
Q3 2021 Nov 15, 2021	BUY	$38.65 - $46.11 $26,939 - $32,138	697 New	697 $27,000

Others Institutions Holding GLSI

# of Institutions

Shares Held

1.24M

Call Options Held

Put Options Held

View Full List

About Greenwich LifeSciences, Inc.

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $119M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

More about GLSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account